Eli Lilly Bets Billions on Unapproved Weight-Loss Pill with Major Texas Facility

Strategic Shift Towards High-Growth Products

Eli Lilly is making an unprecedented $6.5 billion wager on a single facility in Texas, dedicated to a drug that has not yet received regulatory approval. This record-breaking investment is centered on the company’s experimental oral weight-loss medication, Orforglipron, raising questions about the viability of such a high-stakes strategy.

The new Houston plant is designed to become the primary manufacturing hub for Orforglipron. This oral GLP-1 agonist is positioned as a convenient alternative to Lilly’s successful injectable treatments, Mounjaro and Zepbound. This project is a key component of a much larger, $27 billion capital expenditure plan to establish four new US-based sites over the next five years.